Redhill Biopharma (NASDAQ:RDHL) Share Price Crosses Below 200 Day Moving Average – Time to Sell?

Redhill Biopharma Ltd. (NASDAQ:RDHL)’s share price passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $1.34 and traded as low as $0.9950. Redhill Biopharma shares last traded at $0.9950, with a volume of 7,425 shares traded.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Redhill Biopharma in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Redhill Biopharma has an average rating of “Sell”.

Redhill Biopharma Stock Performance

The firm has a fifty day simple moving average of $1.18 and a 200 day simple moving average of $1.34. The company has a market capitalization of $5.08 million, a PE ratio of 0.00 and a beta of 4.91.

Institutional Investors Weigh In On Redhill Biopharma

An institutional investor recently bought a new position in Redhill Biopharma stock. Yorkville Advisors Global LP purchased a new position in Redhill Biopharma Ltd. (NASDAQ:RDHL) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 386,593 shares of the biotechnology company’s stock, valued at approximately $398,000. Redhill Biopharma accounts for approximately 0.3% of Yorkville Advisors Global LP’s investment portfolio, making the stock its 19th largest holding. Yorkville Advisors Global LP owned about 7.57% of Redhill Biopharma at the end of the most recent quarter. Institutional investors and hedge funds own 7.20% of the company’s stock.

About Redhill Biopharma

RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered small molecules for the treatment of inflammatory, gastrointestinal and oncology indications. Founded in 2009 and headquartered in Tel Aviv, Israel, RedHill is publicly traded on the Nasdaq under the symbol RDHL. The company’s strategy centers on in-licensing late-stage clinical candidates and advancing them through regulatory review toward global commercialization.

RedHill’s lead marketed product, Talicia® (formerly RHB-105), is an FDA-approved, three-drug treatment for Helicobacter pylori infection, co-commercialized in the United States through a partnership with Bausch Health.